AR103030A1 - IMMUNOGEN COMPOSITION - Google Patents

IMMUNOGEN COMPOSITION

Info

Publication number
AR103030A1
AR103030A1 ARP150104087A ARP150104087A AR103030A1 AR 103030 A1 AR103030 A1 AR 103030A1 AR P150104087 A ARP150104087 A AR P150104087A AR P150104087 A ARP150104087 A AR P150104087A AR 103030 A1 AR103030 A1 AR 103030A1
Authority
AR
Argentina
Prior art keywords
vaccine
immunogenic composition
years
age
saponin
Prior art date
Application number
ARP150104087A
Other languages
Spanish (es)
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of AR103030A1 publication Critical patent/AR103030A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Reivindicación 1: Una composición inmunógena, por ejemplo de vacuna, que comprende un antígeno gE de virus de varicela zóster (VZV) truncado para eliminar la región de anclaje carboxi terminal, en combinación con un coadyuvante que comprende una saponina, un agonista de TLR-4 y liposomas para su uso en un procedimiento para la protección frente a, o la prevención de, herpes zóster (HZ) y/o neuralgia postherpética (PHN) durante al menos 4 años después de la vacunación. Reivindicación 2: Una composición inmunógena, por ejemplo de vacuna, según la reivindicación 1, para su uso en un procedimiento para la protección frente a, o la prevención de, herpes zóster (HZ) y/o neuralgia postherpética durante al menos 5, 6, 7, 8, 9, 10, 12 ó 15 años después de la vacunación. Reivindicación 5: Composición inmunógena, por ejemplo de vacuna, según cualquiera de las reivindicaciones anteriores, para su uso en un sujeto humano de ³ 50 años de edad, ³ 60 años de edad, ³ 70 años de edad, entre 50 y 59 años de edad o entre 60 y 69 años de edad. Reivindicación 13: Una composición inmunógena, por ejemplo de vacuna, según cualquiera de las reivindicaciones anteriores, en la que el procedimiento comprende administrar 2 dosis de la composición de vacuna a un individuo. Reivindicación 17: Una composición inmunógena, por ejemplo de vacuna, según cualquiera de las reivindicaciones anteriores, en la que el antígeno gE de VZV no está en forma de una proteína de fusión. Reivindicación 20: Una composición inmunógena, por ejemplo de vacuna, según cualquiera de las reivindicaciones anteriores, en la que el antígeno de VZV está presente en una cantidad de 50 mg por dosis. Reivindicación 21: Una composición inmunógena, por ejemplo de vacuna, según cualquiera de las reivindicaciones anteriores, en la que la saponina es QS21. Reivindicación 22: Una composición inmunógena, por ejemplo de vacuna, según cualquiera de las reivindicaciones anteriores, en la que la saponina tal como QS21 está presente en una cantidad de 1 a 100 mg, tal como 25 mg ó 50 mg por dosis.Claim 1: An immunogenic composition, for example a vaccine, comprising a truncated chickenpox virus (VZV) gE antigen to remove the carboxy terminal anchor region, in combination with an adjuvant comprising a saponin, a TLR-agonist. 4 and liposomes for use in a procedure for protection against, or prevention of, shingles (HZ) and / or postherpetic neuralgia (PHN) for at least 4 years after vaccination. Claim 2: An immunogenic composition, for example of a vaccine, according to claim 1, for use in a method for the protection against, or the prevention of, shingles (HZ) and / or postherpetic neuralgia for at least 5, 6 , 7, 8, 9, 10, 12 or 15 years after vaccination. Claim 5: Immunogenic composition, for example of vaccine, according to any of the preceding claims, for use in a human subject of ³ 50 years of age, ³ 60 years of age, ³ 70 years of age, between 50 and 59 years of age. Age or between 60 and 69 years old. Claim 13: An immunogenic composition, for example of a vaccine, according to any of the preceding claims, wherein the method comprises administering 2 doses of the vaccine composition to an individual. Claim 17: An immunogenic composition, for example of a vaccine, according to any of the preceding claims, wherein the VZV gE antigen is not in the form of a fusion protein. Claim 20: An immunogenic composition, for example of a vaccine, according to any of the preceding claims, wherein the VZV antigen is present in an amount of 50 mg per dose. Claim 21: An immunogenic composition, for example of a vaccine, according to any of the preceding claims, wherein the saponin is QS21. Claim 22: An immunogenic composition, for example of a vaccine, according to any of the preceding claims, wherein saponin such as QS21 is present in an amount of 1 to 100 mg, such as 25 mg or 50 mg per dose.

ARP150104087A 2014-12-18 2015-12-15 IMMUNOGEN COMPOSITION AR103030A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201422686 2014-12-18

Publications (1)

Publication Number Publication Date
AR103030A1 true AR103030A1 (en) 2017-04-12

Family

ID=52807451

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150104087A AR103030A1 (en) 2014-12-18 2015-12-15 IMMUNOGEN COMPOSITION

Country Status (2)

Country Link
AR (1) AR103030A1 (en)
BE (1) BE1022523B1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4074336A1 (en) * 2019-12-13 2022-10-19 Grand Theravac Life Science (Nanjing) Co., Ltd. Pharmaceutical composition and use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine

Also Published As

Publication number Publication date
BE1022523B1 (en) 2016-05-20

Similar Documents

Publication Publication Date Title
CL2019003264A1 (en) Formulations for vaccines against neoplasia and methods for preparing the same. (divisional request 201703151)
HRP20210608T1 (en) Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
CO2018005258A2 (en) Herpes simplex virus vaccine
CR20180027A (en) NEW PEPTIDES AND NEW COMBINATIONS OF PEPTIDES FOR USE IN THE SAME THERAPY AGAINST OVARY EPITELIAL CANCER AND OTHER TYPES OF CANCER.
NZ616304A (en) Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CO6501190A2 (en) PCSK9 VACCINE
CO6331297A2 (en) NEW ADVANCING COMPOSITIONS
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
AR108829A1 (en) VACCINE AGAINST INFECTIOUS BRONCHITIS VIRUS
AR093712A1 (en) IMMUNOGEN COMPOSITION, VACCINE, USE AND PROCEDURE FOR PREVENTION OR TREATMENT
BR112017003462A2 (en) attenuated bovine coronavirus, vaccine, and method of vaccination of a bovine.
JP2018500322A5 (en)
BR112014023414A2 (en) recombinant equine herpesvirus-1 vaccine containing a mutant glycoprotein and its uses
CO6561819A2 (en) VECTORS FOR VACCINES AND METHOD FOR POWERING IMMUNE RESPONSES
PH12015501875A1 (en) Acellular pertussis vaccine
MX2016001695A (en) Combination immunogenic compositions.
MX2017013564A (en) Glucopyranosyl lipid a and peanut allergen formulations for sublingual administration.
AR099960A1 (en) PROCEDURES AND PHARMACEUTICAL COMPOSITION TO INDUCE AN IMMUNE RESPONSE
MX2013003245A (en) Bvdv vaccine.
BR112013001946A2 (en) inactivated varicella zoster virus, pharmaceutical composition, method for preparing an inactivated varicella zoster virus, vaccine, and method for treating herpes zoster in an individual
AR104271A1 (en) VACCINE AGAINST PAPERAS BASED ON VIRUS JERYL LYNN 2 RECOMBINANT
AR103030A1 (en) IMMUNOGEN COMPOSITION
AR093530A1 (en) VACCINATION ASSISTANT, PREPARATION, AND VACCINES CONTAINING IT
AR102250A1 (en) COMPOSITIONS OF VACCINES WITH REDUCED FOAM FORMATION
AR106501A1 (en) VACCINE ADJUSTER AND COMPOSITION CONTAINING IT

Legal Events

Date Code Title Description
FB Suspension of granting procedure